Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : I-mab crawled time : 14:00 save search
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
Published: 2023-11-01 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -4.9%
H: 13.24%
C: 12.5%
antibody
AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline
Published: 2023-09-27 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -2.38%
abbvie contract cancer pipeline car-t
AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products
Published: 2023-09-25 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 0.83%
H: 5.79%
C: 5.79%
cd47 partnership abbvie antibody
I-Mab Announces the Appointment of Raj Kannan as CEO
Published: 2023-06-22 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 0.0%
H: 0.98%
C: -2.22%
ceo
Global Hormone Replacement Therapy Market is expected to reach US$ 25.09 Billion by 2027
Published: 2022-12-01 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 0.11%
H: 0.64%
C: 0.64%
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: 0.36%
H: 1.68%
C: 1.53%
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 1.25%
H: 0.2%
C: -0.02%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.18%
H: 0.26%
C: 0.11%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 1.0%
H: 0.11%
C: -1.19%
ABT | News | $106.89 -0.65% -0.09% 4.2M
|
Health Technology
|
| O: 0.61%
H: 0.38%
C: -0.29%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -1.35%
H: 5.48%
C: 1.1%
global expected therapy market hormone
U.S. and China Reportedly Near Deal to Avoid NASDAQ Delisting
Published: 2022-08-26 (Crawled : 14:00) - biospace.com/
MSC | $7.23 -3.46% -4.98% 210
|
Consumer Services
|
| O: -1.14%
H: 8.64%
C: 4.89%
DQ | $23.75 3.22% -0.04% 500K
|
Process Industries
|
| O: 3.43%
H: 6.57%
C: 4.4%
MLCO | $6.27 1.13% 1.27% 4.1M
|
Consumer Services
|
| O: 3.64%
H: 0.17%
C: -1.67%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 5.38%
H: 0.0%
C: -4.31%
nasdaq avoid deal china
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
Published: 2022-08-19 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -3.07%
H: 2.15%
C: 0.17%
report six
Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab
Published: 2022-08-17 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.79%
H: 0.95%
C: 0.01%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -4.39%
H: 0.52%
C: -10.37%
aml trial cancer
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 1.12%
H: 6.39%
C: 2.76%
cd47 antibody phase 2
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
Published: 2022-06-23 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 0.61%
H: 4.84%
C: 3.72%
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
Published: 2022-03-31 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -1.21%
H: 1.52%
C: -13.25%
management
AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
Published: 2022-02-02 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 5.41%
H: 0.0%
C: 0.0%
financial results report results
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 0.0%
H: 1.88%
C: 1.75%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 0.86%
H: 7.74%
C: 5.84%
partnership commercialization drug cel
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
Published: 2022-01-12 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
phase 2
I-Mab Announces Upcoming Participation at January Conferences
Published: 2021-12-31 (Crawled : 14:00) - prnewswire.com
MS | News 0 d | $93.85 0.1% -0.02% 3.3M
|
Finance
|
| O: -0.07%
H: 0.49%
C: -0.58%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -0.67%
H: 4.18%
C: -0.36%
conference
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published: 2021-12-27 (Crawled : 14:00) - biospace.com/
MGNX | $15.7 -3.27% -3.38% 520K
|
Health Technology
|
| O: -0.75%
H: 1.28%
C: -2.84%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -0.49%
H: 2.25%
C: -0.79%
phase 2 solid tumors trial approval china
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 1.36%
H: 6.04%
C: 4.0%
alzheimer treatment disease phase 1 phase 2 alzheimer’s alzheimer's disease alzheimer's
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
Published: 2021-12-07 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -4.02%
H: 0.0%
C: 0.0%
Berkeley Lights Debuts in France as MImAbs Acquires the Beacon® Optofluidic System for Antibody Discovery
Published: 2021-12-02 (Crawled : 14:00) - globenewswire.com
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
antibody
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China
Published: 2021-10-13 (Crawled : 14:00) - biospace.com/
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 2.23%
H: 1.75%
C: 1.14%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 0.41%
H: 4.36%
C: 1.94%
china antibody
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.